Full Text View
Tabular View
No Study Results Posted
Related Studies
Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging
This study has been completed.
Study NCT00288340   Information provided by Vanderbilt University
First Received: February 6, 2006   Last Updated: August 12, 2008   History of Changes

February 6, 2006
August 12, 2008
January 2006
August 2006   (final data collection date for primary outcome measure)
characterize abnormalities in brain structure and function related to schizophrenia [ Time Frame: two scans over a six month period ] [ Designated as safety issue: No ]
characterize abnormalities in brain structure and function related to schizophrenia
Complete list of historical versions of study NCT00288340 on ClinicalTrials.gov Archive Site
 
 
 
Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging
Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging

The goal of the project is to characterize abnormalities in brain structure and function related to schizophrenia. The investigators will use advanced magnetic resonance imaging (MRI) techniques to measure the degree and distribution of neuronal activity during specific cognitive tasks, alterations in neuronal connectivity, and how these are related to disease symptoms and treatment.

The goal of the project is to characterize abnormalities in brain structure and function related to schizophrenia. We will use advanced magnetic resonance imaging (MRI) techniques to measure the degree and distribution of neuronal activity during specific cognitive tasks, alterations in neuronal connectivity, and how these are related to disease symptoms and treatment. We will focus on changes in brain structure and function associated with frequent auditory hallucinations, one of the most disabling manifestations of schizophrenia, and with neuroleptic treatment. In order to address these aims, we will study four groups of subjects:

  1. patients who have frequent auditory hallucinations,
  2. patients who are beginning a regimen of anti-psychotic medication,
  3. patients who do not have frequent hallucinations and are not changing medication strategies, and
  4. age-matched normal controls. Each group will contain 15 subjects for a total of 60.
 
Interventional
Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Pharmacokinetics/Dynamics Study
  • Schizophrenia
  • Schizoaffective Disorder
  • Hallucinations
Device: functional magnetic resonance imaging
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
60
August 2006
August 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

Investigators will study subjects who:

  • Are between the ages of 18 and 65.
  • Meet diagnostic criteria for any psychiatric disorder with auditory hallucinations (at least one every 20 minutes) including schizophrenia/schizoaffective disorder OR schizophrenia/schizoaffective disorder without auditory hallucinations.
  • Have been treated with an antipsychotic drug for hallucinations at least three months or are unmedicated
  • Are willing to change their current antipsychotic medication if indicated
  • Are able to provide written consent

Normal controls must :

  • Be between the ages of 18 and 65
  • Not meet the diagnostic criteria for schizophrenia or schizoaffective disorder or other psychiatric disorder involving hallucinations
  • Not currently be treated with an antipsychotic drug
  • Be able to provide written consent

Exclusion Criteria:

Subjects and normal controls will be excluded from participation if there is:

  • Evidence of non-psychiatric, chronic central nervous system (CNS) disease (such as brain injury or neurological disease)
  • Contraindication to MRI, including prior claustrophobic reaction and severe movement disorder
  • A recent change in menstrual status other than recent changes in oral or implanted contraceptive use (for females)
  • A positive pregnancy result (for females)
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00288340
Adam Anderson, Ph.D., Vanderbilt Medical Center
050978, NARSAD
Vanderbilt University
National Alliance for Research on Schizophrenia and Depression
Principal Investigator: Adam Anderson, Ph.D. Vanderbilt University
Vanderbilt University
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP